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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Serbian language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 248 JIA patients (5.2% systemic, 44.3% oligoarticular, 23.8% RF-negative polyarthritis, 
26.7% other categories) and 100 healthy children were enrolled in three centres. The JAMAR components discriminated 
healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the 
Serbian version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine 
clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Serbian parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient-
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified accord-
ing to the ILAR criteria [5, 6] and enrolled from December 
2011 to November 2012. Children were recruited after Eth-
ics Committee approval and consent from at least one parent.
Rheumatology
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The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, and 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent);
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for par-
ent proxy-report (child’s age 2–18), one for child self-
report, with the suggested age range of 7–18 years, and 
one for adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to the international guidelines with 2–3 forward 
and backward translations. In those countries for which 
the translation of JAMAR had been already cross-cultural 
adapted in a similar language (i.e. Spanish in South Amer-
ican countries), only the probe technique was performed. 
Reading comprehension and understanding of the trans-
lated questionnaires were tested in a probe sample of 10 
JIA parents and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy chil-
dren and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. .In par-
ticular, we evaluated the following validity components: 
the first Likert assumption [mean and standard deviation 
(SD) equivalence]; the second Likert assumption or equal 
item–scale correlations (Pearson r: all items within a scale 
should contribute equally to the total score); third Lik-
ert assumption (item internal consistency or linearity for 
which each item of a scale should be linearly related to the 
total score that is 90% of the items should have Pearson 
r ≥ 0.4); floor/ceiling effects (frequency of items at lower 
and higher extremes of the scales, respectively); internal 
consistency, measured by the Cronbach’s alpha, interscale 
correlation (the correlation between two scales should be 
lower than their reliability coefficients, as measured by 
Cronbach’s alpha); test–retest reliability or intra-class 
correlation coefficient (reproducibility of the JAMAR 
repeated after 1 or 2 weeks); and construct validity in its 
two components: the convergent or external validity which 
examines the correlation of the JAMAR sub-scales with 
the six JIA core set variables, with the addition of the par-
ent assessment of disease activity and pain by the Spear-
man’s correlation coefficients (r) [17] and the discriminant 
validity, which assesses whether the JAMAR discriminates 
between the different JIA categories and healthy children 
[18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Serbian parent and patient versions of the 
JAMAR are available upon request to PRINTO.
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Results
Cross‑cultural adaptation
The Serbian JAMAR was fully cross-culturally adapted 
from the standard English version with three forward 
and two backward translations with a concordance for 
116/123 translations lines (94.3%) for the parent version 
and 116/120 lines (96.7%) for the child version.
In the probe technique analysis all the 123 lines of the par-
ent version of the JAMAR were understood by at least 80% 
of the 10 parents tested (median 100%; range 90–100%). 
All the 120 lines of the patient version of the JAMAR were 
understood by at least 80% of the children (median 100%; 
range 90–100%). The texts of the parent JAMAR and of the 
child JAMAR were unmodified after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 249 JIA patients and 100 healthy children (total 
of 349 subjects) were enrolled at three paediatric rheuma-
tology centres. One patient did not give the consent to use 
his/her data.
In the 248 JIA subjects, the JIA categories were 5.2% 
with systemic arthritis, 44.3% with oligoarthritis, 23.8% 
with RF-negative polyarthritis, 4.4% with RF-positive pol-
yarthritis, 2.4% with psoriatic arthritis, 15.7 with enthesi-
tis-related arthritis and 4.0% with undifferentiated arthritis 
(Table 1).
A total of 348/348 (100%) subjects had the parent version 
of the JAMAR completed by a parent (248 from parents of 
JIA patients and 100 from parents of healthy children). The 
JAMAR was completed by 293/348 (84.2%) mothers and 
55/348 (15.8%) fathers. The child version of the JAMAR 
was completed by 228/348 (65.5%) children age 5.8 or older. 
Also patients younger than 7 years, capable to assess their 
personal condition and able to read and write, were asked to 
fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the 
PF, the PhH, the PsH subscales and total score of the 
HRQoL scales. The JAMAR components discriminated 
well between healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. “Results” 
refer mainly to the parent’s version findings, unless other-
wise specified.
Descriptive statistics (first Likert assumption)
For all the JAMAR items the median number of missing 
responses was 0.8 (0.4–1.2).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items except for items 8 and 9, whereas a reduced 
number of response choices were used for PF items 9, 11, 
12, 13, 14 and 15.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown). The median number of items marked as 
not applicable was 0% (0–1%) for the PF and 5.5% (2–20%) 
for the HRQoL.
Floor and ceiling effect
The median floor effect was 88.3% (86.3–95.6%) for the PF 
items, 69.8% (57.7–70.2%) for the HRQoL-PhH items, and 
65.3% (48.8–69.4%) for the HRQoL-PsH items. The median 
ceiling effect was 0.8% (0–1.2%) for the PF items, 1.2% 
(1.2–3.2%) for the HRQoL-PhH items, and 0.8% (0–1.2%) 
for the HRQoL-PsH items. The median floor effect was 
38.3% for the pain VAS, 35.9% for the disease activity VAS 
and 43.1% for the well-being VAS. The median ceiling effect 
was 0% for the pain VAS, 0.4% for the disease activity VAS 
and 0% for the well-being VAS.
Equal item–scale correlations (second Likert 
assumption)
Pearson item–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 80% of the 
PF items, with the exception of PF items 9, 10, and 11, and 
for 100% of the HRQoL items.
Items internal consistency (third Likert assumption)
Pearson item–scale correlations were ≥ 0.4 for 73.3% of 
items of the PF (except for PF items 9, 11, 12 and 15) and 
100% of items of the HRQoL.
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Table 1  Descriptive statistics (medians, 1st–3rd quartiles or absolute frequencies and %) for the 348 JIA patients
Systemic Oligoar-
thritis
RF − poly-
arthritis
RF + poly-
arthritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undif-
ferentiated 
arthritis
All JIA 
patients
Healthy
N = 13 N = 110 N = 59 N = 11 N = 6 N = 39 N = 10 N = 248 N = 100
Female 3 (23.1%) 83 (75.5%) 50 (84.7%) 10 (90.9%) 3 (50%) 2 (5.1%) 9 (90%) 160 
(64.5%)#
49 (49%)*
Age at visit 11.1 
(10–13)
8.6 (5.7–
13.6)
13.7 
(9.5–17)
17 (12.6–
18.4)
16.3 (14.3–
20.3)
14.6 (11.8–
16.9)
7.3 (4.7–
15.3)
12.2 
(7–15.8)#
9 (5.9–12)#
Age at onset 4.5 
(3.6–7.6)
3.5 
(1.9–7.2)
9.2 (5.1–13) 11.8 
(8.2–12.2)
12.8 
(9.7–15.4)
10.6 
(9.3–12.4)
4.6 (2.3–
11.1)
6.9 (2.6–
11.4)#
Disease dura-
tion
4.5 
(2.9–6.6)
4 (1.8–6.5) 3.7 
(1.9–5.1)
4.9 
(2.8–7.8)
3.4 
(1.1–5.4)
3.2 
(1.6–5.4)
1.4 
(0.3–4.4)
3.7 
(1.8–5.9)
ESR 9 (7–12) 10 (6–12) 10.5 
(6.5–14)
10.5 (6–16) 7.5 (6–9) 10 (5–18) 20 (18–40) 10 (6–14)*
MD VAS 
(0–10 cm)
0 (0–1) 0 (0–1) 1 (0–3) 3 (1–5) 2 (1–3.5) 1 (0–2) 1.5 
(0.5–4.5)
0 (0–2)**
No. of swollen 
joints
0 (0–0) 0 (0–1) 0 (0–4) 0 (0–2) 0 (0–3) 0 (0–2) 1.5 (1–4) 0 (0–2)
No. of joints 
with pain
0 (0–2) 0 (0–1) 0 (0–3) 1 (0–4) 0 (0–3) 0 (0–2) 1.5 (1–4) 0 (0–2)*
No. of joints 
with LOM
0 (0–2) 0 (0–1) 0 (0–4) 3 (1–5) 1 (0–1) 1 (0–2) 2 (0–3) 0.5 (0–2)*
No. of active 
joints
0 (0–1) 0 (0–1) 0 (0–4) 0 (0–3) 0 (0–3) 0 (0–2) 1.5 (1–4) 0 (0–2)
Active systemic 
features
0 (0%) 2 (1.8%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (20%) 4/246 
(1.6%)
ANA status 0 (0%) 35 (31.8%) 4 (6.8%) 0 (0%) 0 (0%) 0 (0%) 2 (20%) 41 
(16.5%)**
Uveitis 0 (0%) 15/109 
(13.8%)
5 (8.5%) 0 (0%) 0 (0%) 6 (15.4%) 3 (30%) 29 (11.7%)
PF total score 0 (0–7) 0 (0–1) 1 (0–4) 0 (0–4) 0 (0–0) 1 (0–3) 3 (0–5) 0 (0–3)* 0 (0–0)#
Pain VAS 0 (0–3) 0 (0–1) 1 (0–4) 2 (1–4.5) 1.3 (1–1.5) 1 (0.5–3.5) 2.8 (0–5) 0.5 
(0–2.5)**
0 (0–0)#
Disease activity 
VAS
1 (0–3) 0 (0–2) 1 (0.5–3.5) 1.5 (1–4) 1 (1–1.5) 1 (0–3) 3.8 (0.5–5) 1 (0–3)*
Well-being 
VAS
0.5 (0–2.5) 0 (0–1) 1 (0–3.5) 1.5 
(0.5–4.5)
1 (0–1.5) 1 (0–3) 2 (0–5) 0.5 (0–2)**
HRQoL-PhH 0 (0–2) 1 (0–3) 1 (0–3) 2 (1–3) 1 (1–1) 3 (0–4) 3.5 (0–7) 1 (0–3)* 0 (0–0)#
HRQoL-PsH 1 (0–3) 1 (0–3) 2 (0–4) 4 (2–6) 3 (2–4) 2 (0–4) 1 (0–3) 2 (0–3) 0 (0–3)**
HRQoL total 
score
2 (0–5) 3 (0–6) 4 (1–7) 6 (3–10) 4 (3–5) 5 (2–9) 5.5 (0–13) 3 (0–7) 0 (0–3)#
Pain/swell. in 
> 1 joint
5 (38.5%) 49 (44.5%) 36 (61%) 7 (63.6%) 1 (16.7%) 25 (64.1%) 8 (80%) 131 
(52.8%)*
0 (0%)#
Morning stiff-
ness > 15 min
3 (23.1%) 9/109 
(8.3%)
10 (16.9%) 2 (18.2%) 0 (0%) 7 (17.9%) 4 (40%) 35/247 
(14.2%)
0 (0%)#
Subjective 
remission
4 (30.8%) 37/107 
(34.6%)
30 (50.8%) 5 (45.5%) 2 (33.3%) 18 (46.2%) 8 (80%) 104/245 
(42.4%)*
In treatment 9 (69.2%) 66/108 
(61.1%)
46 (78%) 10 (90.9%) 5/5 (100%) 33 (84.6%) 9 (90%) 178/245 
(72.7%)**
Reporting side 
effects
1/9 (11.1%) 10/66 
(15.2%)
14/46 
(30.4%)
2/10 (20%) 1/5 (20%) 4/32 
(12.5%)
2/8 (25%) 34/176 
(19.3%)
Taking medica-
tion regularly
9/9 (100%) 63/66 
(95.5%)
45/46 
(97.8%)
9/10 (90%) 5/5 (100%) 33/33 
(100%)
7/8 (87.5%) 171/177 
(96.6%)
With problems 
attending 
school
1/9 (11.1%) 1/57 (1.8%) 3/35 (8.6%) 2/8 (25%) 0 (0%) 6/28 
(21.4%)
1/4 (25%) 14/144 
(9.7%)*
0 (0%)*
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.88 for PF-LL, 0.77 for PF-HW, and 
0.61 for PF-US. Cronbach’s alpha was 0.86 for HRQoL-PhH 
and 0.81 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after a 
median of 7 days (7–8 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC = 0.80). The ICC for the HRQoL-PhH 
showed an almost perfect reproducibility (ICC = 0.95) while 
the ICC for the HRQoL-PsH showed a substantial reproduc-
ibility (ICC = 0.79).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.4 to 0.6 
(median = 0.5). The PF total score best correlation was 
observed with the parent global assessment of well-being 
(r = 0.6, p < 0.001). For the HRQoL, the median correla-
tion of the PhH with the JIA core set of outcome variables 
ranged from 0.4 to 0.7 (median = 0.6), whereas for the PsH 
ranged from 0.2 to 0.5 (median = 0.4). The PhH showed the 
best correlation with the parent’s assessment of pain (r = 0.7, 
p < 0.001) and the PsH with the parent global assessment 
of well-being (r = 0.6, p < 0.001). The median correlations 
between the pain VAS, the well-being VAS, and the disease 
activity VAS and the physician-centred and laboratory 
measures were 0.4 (0.3–0.5), 0.4 (0.3–0.5), 0.5 (0.4–0.6), 
respectively.
Discussion
In this study, the Serbian version of the JAMAR was cross-
culturally adapted from the original standard English version 
with three forward and two backward translations. Accord-
ing to the results of the validation analysis, the Serbian par-
ent and patient versions of the JAMAR possess satisfactory 
psychometric properties. The disease-specific components 
of the questionnaire discriminated well between patients 
with JIA and healthy controls. All the JAMAR components 
revealed to be able to discriminate between the different JIA 
subtypes with the children diagnosed with undifferentiated 
arthritis having a higher degree of disability.
Psychometric evaluation was good for all the HRQoL 
items but not for all the PF domains: four PF items (“open 
a door by lowering the handle”, “stretch arms”, “put hands 
behind the neck” and “bite a sandwich or an apple”) showed 
a lower items internal consistency and also internal consist-
ency for the PF-US was modest.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from moderate to strong.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
Data related to the JAMAR refer to the 248 JIA patients and to the 100 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD Medical Doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL Health-Related Quality of Life (total score ranges from 0 to 30), PhH Physical Health (total score ranges 
from 0 to 15), PsH Psychosocial Health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05 **p < 0.001 #p < 0.0001
Table 1  (continued)
Systemic Oligoar-
thritis
RF − poly-
arthritis
RF + poly-
arthritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undif-
ferentiated 
arthritis
All JIA 
patients
Healthy
N = 13 N = 110 N = 59 N = 11 N = 6 N = 39 N = 10 N = 248 N = 100
Satisfied with 
disease out-
come
11 (84.6%) 76/109 
(69.7%)
37 (62.7%) 7 (63.6%) 4 (66.7%) 23 (59%) 3 (30%) 161/247 
(65.2%)*
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In conclusion, the Serbian version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA Juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
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Floor effect, median
 PF 88.3% 87.9%
 HRQoL-PhH 69.8% 72.8%
 HRQoL-PsH 65.3% 71.1%
 Pain VAS 38.3% 34.7%
 Disease activity VAS 35.9% 39.9%
 Well-being VAS 43.1% 39.9%
Ceiling effect, median
 PF 0.8% 0.6%
 HRQoL-PhH 1.2% 1.2%
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 PF-HW 0.77 0.79
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 HRQoL-PsH 0.81 0.81
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Test–retest intraclass correlation
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and its translations must be obtained in writing from PRINTO, Genoa, 
Italy. All JAMAR-related inquiries should be directed to at printo@
gaslini.org. Permission for use of CHAQ and CHQ-derived material 
is granted through the scientific cooperation of the copyright holder 
ICORE of Woodside CA and HealthActCHQ Inc. of Boston, Massa-
chusetts USA. All CHQ-related inquiries should be directed to licens-
ing@healthactchq.com. All CHAQ-related inquiries should be directed 
to gsingh@stanford.edu.
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